LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

Actual Patient

LEMTRADA CLINICAL RESULTS

LEMTRADA CAN HELP
REDUCE RELAPSES*

*In two 2-year clinical trials against Rebif® (interferon beta-1a) 44 mcg

People who took LEMTRADA had half as many relapses as people who took Rebif

The annual relapse rate was 0.26 for LEMTRADA vs 0.52 for Rebif.

Patients were treated with LEMTRADA for 2 years and were then invited to continue in an Extension Study for an additional 4 years, for a total of 6 years in the studies.

2 out of 3 people icon.

who took LEMTRADA were living relapse-free at 2 years vs nearly 1 out of 2 people who took Rebif.

 
Study 1 Extension, years 3-6.

The annual percentage of people in the Extension Study who took LEMTRADA and were living relapse-free ranged from

79% to 87%.

There were 628 people in the 2-year study (Study 1), with 426 taking LEMTRADA and 202 taking Rebif. 9 out of 10 people (387) who took LEMTRADA entered the Study 1 Extension, with most (332) continuing through 4 years.

LEMTRADA MAY SLOW DISABILITY PROGRESSION

SECONDARY
INFORMATION IN
STUDY 1
SECONDARY
INFORMATION IN
STUDY 1
87% of people icon.

13% of patients who took LEMTRADA experienced confirmed disability progression compared with 21% of those who took Rebif.

A separate study in patients showed no statistically significant difference in confirmed disability progression between LEMTRADA and Rebif.

Confirmed disability progression was defined as at least a 1-point increase (1.5 for patients starting at 0) on the Expanded Disability Status Scale (EDSS) that lasts for 6 months.

SECONDARY
INFORMATION IN
STUDY 1
Study 1 extension at year 6.
7 out of 10 people icon.

who were in the Extension Study had no confirmed disability progression.

Listed below are tertiary results from LEMTRADA clinical trials. Tertiary results are not tested for statistical significance. No definitive conclusions about treatment effects of LEMTRADA or Rebif can be drawn from these tertiary data.

At year 2, 85% of patients who took LEMTRADA had stabilized or improved disability vs 75% of people who took Rebif.

LEMTRADA Rebif
28.8% Improved Disability 16.0%
55.9% Stabilized Disability 58.9%
15.3% Worsened Disability 25.1%

At year 6, 77% of patients who took LEMTRADA had stabilized or improved disability.

LEMTRADA    
23.6% Improved Disability  
53.7% Stabilized Disability  
22.7% Worsened Disability  

IMPROVED DISABILITY

1-point or greater decrease in EDSS score.

STABILIZED DISABILITY

Change in EDSS score of 0.5 points or less.

WORSENED DISABILITY

1-point or greater increase in EDSS score.

Important Safety Information See More

LEMTRADA can cause serious side effects including serious autoimmune problems. Some people receiving LEMTRADA develop a condition where the immune cells in your body attack other cells or organs in the body (autoimmunity), which can be serious and may cause death. Serious autoimmune problems may include: